Skip to main content
Hua-Jay Cherng, MD, Oncology, New York, NY

Hua-JayJefferyCherngMD(He/Him)

Oncology New York, NY

Hematologic Oncology

Assistant Professor of Medicine

Overview of Dr. Cherng

Dr. Hua-Jay Cherng is a New York-based oncologist with a subspecialty in hematologic oncology. He has been educated and trained at prestigious institutions, starting at Case Western Reserve University School of Medicine, followed by his internship and residency at University of Pennsylvania Health System, and his fellowship at University of Texas Health Science Center at Houston/M D Anderson Cancer Center. Professional experience ranges from Resident Physician at the Hospital of the University of Pennsylvania to Clinical Fellow at University of Texas M.D. Anderson Cancer Center. His expertise lies in internal medicine and medical oncology. He has an impressive list of publications in esteemed journals, discussing various aspects of lymphoma, DLBCL treatment, and CAR T-cell therapy.

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemInternship, Internal Medicine, 2016 - 2019
  • Pennsylvania Hospital of the University of Pennsylvania Health System
    Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 2016 - 2019
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2016

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2022 - 2025
  • TX State Medical License
    TX State Medical License 2019 - 2024
  • PA State Medical License
    PA State Medical License 2018 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Press Mentions

  • Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma Patients
    Foresight Diagnostics Announces Launch of SHORTEN-ctDNA Trial to Evaluate Personalized Treatment Duration in DLBCL Lymphoma PatientsDecember 5th, 2024

Other Languages

  • Chinese (Mandarin)